Nearly One-Third of Mesothelioma Patients Remain Untreated

A new report from the National Cancer Institute (NCI) shows between 20 and 30 percent of malignant mesothelioma patients do not receive any cancer treatment. The study, “Patterns of care and survival among patients with malignant mesothelioma in the United States,” published August 10 in the journal Lung Cancer, aimed to describe the patterns of care and subsequent survival among mesothelioma patients in the U.S. while adjusting for patient demographics and pre-existing health conditions. Using the NCI’s Surveillance, Epidemiology, and End Results (SEER) data, researchers discovered significant differences in treatment patterns and overall survival between pleural mesothelioma patients and nonpleural patients. Mesothelioma patients diagnosed with the pleural type and older than 70 were less likely to receive therapy compared to peritoneal mesothelioma patients and those diagnosed at younger ages. Key findings included: 29.3 percent of pleural mesothelioma patients do not receive treatment Pleural patients tended to be older and male (78.9 percent) Median survival was eight months for pleural patients and 18 months for nonpleural patients Pleural mesothelioma patients who received surgery and chemotherapy showed the best overall survival “These findings indicate the need for efforts to ensure equitable application of currently available therapies to all patients,” lead author Lindsey Enewold wrote in the study. Chemotherapy: Most Common Me...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: amount of mesothelioma patients eligible for surgery checkpoint inhibitors clinical trial enrollment cytoreduction surgery heated chemotherapy pleural mesothelioma heated intraperitoneal chemotherapy immunotherapy mesothelioma keytruda Lin Source Type: news

Related Links:

The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Although mesothelioma is the consequence of a protracted immune response to asbestos fibers and characterized by a clear immune infiltrate, novel immunotherapy approaches show less convincing results as compared to those seen in melanoma and non-small cell lung cancer. The immune suppressive microenvironment in mesothelioma is likely contributing to this therapy resistance. Therefore, it is important to explore the characteristics of the tumor microenvironment for explanations for this recalcitrant behavior. This review describes the stromal, cytokine, metabolic, and cellular milieu of mesothelioma, and attempts to make co...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
(Impact Journals LLC) Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system. Comparing NSCLC PE and published plasma levels of CAR-T recipients, both were dominated by sIL-6R and IL-6 but NSCLC PE had more VEGF, FGF2 and TNF, and less IL-2, IL-4, IL-13, IL-15, MIP1 and IFN.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Conditions:   Non Small Cell Lung Cancer;   Non-squamous Non-small-cell Lung Cancer;   Urothelial Carcinoma;   Malignant Mesothelioma Interventions:   Drug: Cabozantinib;   Drug: Pemetrexed Sponsor:   Augusta University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Introduction: Malignant pleural mesothelioma (MPM) is a rare disease with poor prognosis. Previous preclinical studies have shown that activin A is overexpressed in MPM and this overexpression is associated with cancer cachexia and resistance to platinum-based chemotherapy. We evaluated circulating activin levels and its endogenous antagonist follistatin/FSTL3 in thoracic malignancy.Methods: Patients suspected of thoracic malignancy were prospectively recruited prior to either diagnostic or therapeutic surgery. Serum samples were collected from 21 patients with MPM, 59 patients with non-small-cell lung cancer (NSCLC), 22 p...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Pleural and mediastinal malignancies Source Type: research
Authors: Donnenberg AD, Luketich JD, Donnenberg VS Abstract INTRODUCTION: We compared the secretome of metastatic (non-small cell lung cancer (NSCLC)) and primary (mesothelioma) malignant pleural effusions, benign effusions and the published plasma profile of patients receiving chimeric antigen receptor T cells (CAR-T), to determine factors unique to neoplasia in pleural effusion (PE) and those accompanying an efficacious peripheral anti-tumor immune response. MATERIALS AND METHODS: Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytok...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Nivolumab is a fully human, immunoglobulin G4 (kappa) isotype monoclonal antibody that binds programmed cell death protein 1 (PD-1) on activated immune cells and disrupts the engagement of the receptor with its ligands programmed death-ligand 1 (PD-L1: B7-H1/CD274 and PD-L2: B7-DC/CD273), thereby abrogating inhibitory signals and augmenting the antitumor response of the host [1]. In previous clinical trials, nivolumab has shown activity in several tumor types, including melanoma, renal cell carcinoma, non-small cell lung cancer (NSCLC), hodgkin lymphoma, and malignant pleural mesothelioma.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Researchers at Osaka University in Japan have identified a key component of physical health associated with response to immunotherapy drugs. Among people with non-small cell lung cancer, higher levels of muscle mass predicted a better response to PD-1 inhibitor immunotherapy. Sarcopenia — the term used to describe low muscle mass levels — appears to reduce the benefits a person receives from immunotherapy cancer treatment. “Sarcopenia at baseline is a significant predictor of worse outcome in patients with advanced NSCLC [non-small cell lung cancer] receiving PD-1 blockade,” the study investigators ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Doctors at the Princess Margaret Cancer Center in Toronto are studying the use of hypofractionated radiation to increase the effectiveness of immunotherapy for patients with mesothelioma. They are expected to launch soon a clinical trial that will add an immunotherapy combination to the high-dose radiation and aggressive surgery mix that has been so successful in Toronto. “There are a lot of questions that still need to be answered, but if I was a betting man, I’d lay odds on it [working well],” Dr. John Cho of the cancer center’s clinical research unit, told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
We're making progress in the fight against malignant pleural mesothelioma. Doctors are treating it more aggressively. New drugs are emerging. Survivors are living longer. Therapies are becoming more precise and individualized. And specialty centers are becoming more prominent and comprehensive. Even the highly criticized U.S. Department of Veterans Affairs (VA) is taking it more seriously now. There is growing hope on the horizon. Here are the most prominent stories of 2015, providing a glimpse of what will come in 2016. FDA Approves Keytruda and Opdivo for Lung Cancer The U.S. Food and Drug Administrati...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Environmental Health | Epidemiology | Food and Drug Administration (FDA) | Immunotherapy | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Radiation Therapy | Study | USA Health